Veterinary Medicines

CANIXIN Pi/L lyophilisate and suspension for suspension for injection for dogs

Authorised
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
  • Canine parainfluenza virus, strain Manhattan, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
Download as PDF

Product identification

Medicine name:
CANIGEN PI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS
CANIXIN Pi/L lyophilisate and suspension for suspension for injection for dogs
Active substance:
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
  • Canine parainfluenza virus, strain Manhattan, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
    4350.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Canine parainfluenza virus, strain Manhattan, Live
    4.80
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
    4250.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI08
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Package description:
  • Plastic box of 1 vial of lyophilisate and 1 vial of suspension
  • Cardbox of 100 vials of lyophilisate and 100 vials of suspension
  • Cardbox of 50 vials of lyophilisate and 50 vials of suspension
  • Cardbox of 25 vials of lyophilisate and 25 vials of suspension
  • Cardbox of 10 vials of lyophilisate and 10 vials of suspension
  • Cardbox of 1 vial of lyophilisate and 1 vial of suspension
  • Plastic box of 100 vials of lyophilisate and 100 vials of suspension
  • Plastic box of 50 vials of lyophilisate and 50 vials of suspension
  • Plastic box of 25 vials of lyophilisate and 25 vials of suspension
  • Plastic box of 10 vials of lyophilisate and 10 vials of suspension

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10988/103/001
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0311/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."